Bsense Bio Therapeutics

Neuropathic Pain Treatment

Health Tech & Life Sciences
Active
Seed , Israel Founded 2018
Website ↗
Last updated 2026-06-18
Total raised
$2.7M
Last: 2018-09
Stage
Seed
Founded
2018
Headcount
6
HQ
, Israel
Sector
Health Tech & Life Sciences

About

Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. The company is pioneering a novel approach that targets multiple pain-related mechanisms using a single compound to achieve greater efficacy and safety. Bsense Bios approach is based on the targeting of two cation channels, a ligand-gated and a voltage-gated potassium channel (TRPV1 and Kv7.2/3, respectively), which are co-localized on sensory nociceptive neurons and are widely recognized as prominent players in pain signaling. Bsense is currently assessing in depth the specificity and selectivity in vitro of three lead compounds with the purpose of progressing into in vivo safety and efficacy studies. In addition, the company is performing structural activity relation studies to assess whether they can improve the compounds characteristics to achieve a backup compound series. The company is financed by Takeda Ventures Inc, OrbiMed Israel Partners, Johnson & Johnson Innovation (JJDC), and the Israel Innovation Authority (IIA). Bsense Bio Therapeutics was founded at the FutuRx biotech incubator.

Funding history · 1 round · $2.7M total

2018-09

Q&A

What is Bsense Bio Therapeutics' primary focus?
Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain, pioneering a novel approach that targets multiple pain-related mechanisms using a single compound.
When was Bsense Bio Therapeutics founded?
Bsense Bio Therapeutics was founded in September 2018.
How many employees does Bsense Bio Therapeutics have?
Bsense Bio Therapeutics has 1-10 employees.
What is Bsense Bio Therapeutics' total funding to date?
Bsense Bio Therapeutics has raised a total of $2,700,000.
Which investors participated in Bsense Bio Therapeutics' funding round?
The funding round in September 2018 included Johnson & Johnson Innovation and OrbiMed.
What is the current stage of Bsense Bio Therapeutics' product development?
Bsense Bio Therapeutics is currently assessing the specificity and selectivity in vitro of three lead compounds and performing structural activity relation studies, with the goal of progressing into in vivo safety and efficacy studies.
Who is a founder of Bsense Bio Therapeutics?
Prof. Bernard Attali is a founder of Bsense Bio Therapeutics.
What is the core scientific approach of Bsense Bio Therapeutics?
Bsense Bio Therapeutics' approach targets two cation channels, TRPV1 and Kv7.2/3, which are co-localized on sensory nociceptive neurons and are recognized as key players in pain signaling.

Team · 1

Prof. Bernard Attali
Founder · Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B

Highlights

Verified

Tags

pharmaceuticalsneurologybiotechnologydiabetestargeted-therapytreatmentspharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitefuturx.co.il/cgi-sys/suspendedpage.cgi

Identifiers & details

Founded2018-9
Employees (exact)6

Radar intelligence

Patents

EPO2

Web history (Wayback)

Domainfuturx.co.il

Certificate / subdomain footprint

Subdomains10